What is a Trial Master File?
A Trial Master File (TMF) is the complete documentary record of a clinical trial. It contains every essential document that demonstrates the conduct of the trial, the protection of participants, and the reliability of the data — from the first protocol draft through to final close-out.
The TMF is a regulatory requirement. Under ICH E6(R2) Good Clinical Practice guidelines, sponsors are required to maintain a TMF that allows reconstruction of the trial’s conduct and evaluation at any point. This requirement applies whether the trial is run by a sponsor directly, a Contract Research Organisation (CRO), or a hybrid of both.
Regulators from the EMA, FDA, MHRA, and other agencies may request access to the TMF at any time during or after the conduct of a trial. A disorganised, incomplete, or inaccurate TMF is one of the most common sources of inspection findings across Europe and the United States.
What does a TMF contain?
The structure and content of a TMF is governed by the CDISC TMF Reference Model, the industry standard that defines which documents belong in which zones and artefacts within a TMF. The current version is the CDISC TMF Reference Model v3.3.1.
A complete TMF typically contains documents across these major zones:
Trial Management — the administrative backbone of the study. Protocol versions, amendments, IRB/IEC approvals, regulatory authority approvals, and trial registration records.
Site Management — documents specific to each investigational site. Site selection documentation, initiation visit reports, monitoring visit reports, and correspondence between sponsor and site.
Regulatory — all interactions with competent authorities. Submissions, approvals, notifications, and responses to authority queries.
Investigational Product — documentation of the trial product itself. Manufacturing records, certificates of analysis, shipping and accountability logs, and return or destruction records.
Safety Reporting — serious adverse event reports, safety updates, and data monitoring committee records.
Statistics and Data Management — randomisation documentation, data management plans, statistical analysis plans, and the final statistical output.
Central and Local Laboratory — laboratory certifications, normal reference ranges, and specimen tracking documentation.
Ethical and Regulatory Oversight — IRB/IEC correspondence, informed consent form versions, and participant-facing materials.
Within each zone, documents are filed to specific artefacts — defined document types with their own expected attributes, versions, and relationships to other documents. Incorrect artefact classification is one of the most commonly flagged TMF deficiencies during inspections.
What is an eTMF?
An eTMF (electronic Trial Master File) is a digital system purpose-built to store, manage, and maintain a TMF in compliance with regulatory requirements. Unlike a shared drive or a generic document management system, an eTMF is specifically designed around clinical trial requirements — CDISC TMF Reference Model structure, 21 CFR Part 11 compliance for electronic records and signatures, and full audit trail functionality.
Under FDA 21 CFR Part 11 and EMA GCP regulations, any electronic system used to maintain trial records must meet strict requirements for data integrity, access control, audit trails, and validated functionality. A standard file-sharing tool does not meet these requirements.
The Menken Trials eTMF is built around the CDISC TMF Reference Model v3.3.1, with over 500 automated compliance checks running on every document the moment it is uploaded — checking document type, version alignment, signature requirements, and cross-references to other study documents in real time.
What does TMF inspection readiness mean?
Inspection readiness does not mean preparing your TMF for inspection. It means your TMF is ready for inspection at any moment — not because you spent two weeks cleaning it up before the inspectors arrived, but because it has been maintained correctly throughout the study.
Inspectors are experienced at distinguishing a TMF that has been continuously maintained from one that has been retrospectively organised. A document uploaded three days before inspection close carries a different metadata timestamp than one uploaded at the time of the activity it documents. These discrepancies are flagged.
True inspection readiness requires:
Contemporaneous filing. Documents filed at the time of the activity they document, not retrospectively. Consent forms uploaded the day they are signed. Visit reports uploaded within the agreed timeframe after the monitoring visit.
Complete artefact coverage. Every required artefact for the trial’s phase, indication, and geography contains at least one document. Gaps in required artefacts are typically inspection findings.
Version integrity. Every document in the TMF references the correct, current version of related documents. A consent form that references protocol version 3.0 when the active version at that site was 3.1 is a cross-reference discrepancy — a common inspection finding.
Accurate metadata. Document date, version number, and site attribution accurately reflect the content of the document. Incorrect metadata — even when the document itself is correct — is a finding.
Current delegations and qualifications. Every person performing a delegated task has a current delegation log entry and a current training record for that task. GCP certificates and CVs are valid for the period during which the person was active on the study.
The most common TMF inspection findings
Based on EMA GCP Inspectors Working Group annual reports, the most frequently cited TMF deficiencies include:
- Missing or incomplete investigator site file documents
- Delegation log entries not supported by corresponding training records
- GCP certificates that had expired during the conduct period
- Protocol deviation documentation missing or filed late
- Informed consent forms referencing superseded protocol versions
- Monitoring visit reports not filed within the required timeframe
- Essential documents missing at trial initiation
Most of these findings share a common characteristic: they were detectable long before the inspection. They accumulated quietly during the study because no continuous checking mechanism existed to catch them as they occurred.
How Menka AI maintains TMF inspection readiness continuously
Menka AI, built into the Menken Trials platform, runs over 500 automated compliance checks on every document the moment it enters the eTMF — checking artefact classification, version alignment, signature requirements, delegation-to-training cross-references, and expiry dates.
When a GCP certificate is 60 days from expiry, Menka AI sends a reminder. When a document references a protocol version that does not exist in the TMF, Menka AI flags it. When a delegation log entry exists without a corresponding training record, Menka AI catches it — immediately, not at close-out.
Your team can ask Menka AI plain-language questions: “Are we inspection-ready right now?” or “What is missing from Zone 4?” and receive a specific answer.
The result: zero inspection findings related to the Menken Trials platform across every client, every study, ever.
Frequently asked questions
What is the difference between a TMF and an ISF? The Trial Master File is maintained by the sponsor and contains the complete study-level documentation. The Investigator Site File (ISF) is maintained at the investigational site and contains site-level documents. In a compliant study, the two files are mirror images of each other for documents that exist in both — the same document, filed in both places, at the same time. Discrepancies between the TMF and ISF are a common inspection finding. The Menken Trials eISF is directly connected to the eTMF and monitored by Menka AI simultaneously.
How long must a TMF be retained after trial close-out? Under ICH E6(R2), essential documents must be retained for at least two years after the last approval of a marketing application in an ICH region, or for at least two years after the formal discontinuation of clinical development. Many sponsors retain documents for 15 years or longer. Your TMF must remain accessible and legible throughout the retention period.
Who is responsible for maintaining the TMF? The sponsor is ultimately responsible for TMF maintenance, even when a CRO has been delegated operational responsibilities. Where a CRO maintains the TMF on behalf of the sponsor, the sponsor retains regulatory accountability and must have oversight procedures in place.
What is the CDISC TMF Reference Model? The CDISC TMF Reference Model is the industry standard that defines the structure, zones, and artefacts of a compliant TMF. It is maintained by CDISC and updated periodically in collaboration with industry and regulators. Version 3.3.1 is the current release. Most eTMF systems, including Menken Trials, are built around this reference model.
Can a TMF be fully electronic? Yes. Regulators including the EMA and FDA accept fully electronic TMFs, provided the system meets the requirements for electronic records and electronic signatures under EMA GCP guidelines and FDA 21 CFR Part 11 respectively. The system must have a validated audit trail, access controls, and data integrity protections.
Want to see your TMF through Menka AI’s eyes?
We run 15-minute sessions where we show you what Menka AI would find in a real study scenario relevant to what your team is running. No pitch, no demo theatre — just the platform working on a problem that matters to you.
Menken Trials is a clinical trial compliance platform. The Menken Trials eTMF is built around the CDISC TMF Reference Model v3.3.1 and is monitored continuously by Menka AI.
